πŸ‡ΊπŸ‡Έ FDA
Patent

US 10450382

Anti-complement C1s antibodies

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 10450382 (Anti-complement C1s antibodies) held by Bioverativ USA Inc. expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Bioverativ USA Inc.
Grant date
Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K49/00